drugset / Trial / NCT06595017

Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome

NCT06595017

Phase 2 Not yet recruiting 75 enrolled Misr University for Science and Technology
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to investigate the effectiveness of Magnesium Sulphate in the management of myofascial pain dysfunction syndrome in comparison to Lidocaine and Saline. A total of 75 patients suffering from myofascial pain dysfunction syndrome will be assigned into one of three groups, each with 25 patients. Group A: (Saline) includes patients enrolled for Saline injection into the trigger points. Group B: (Magnesium Sulphate) includes patients enrolled for Magnesium Sulphate injection into the trigger points. Group C: (Lidocaine) includes patients who will be enrolled for Lidocaine injection into the trigger points The primary outcome that will be investigated is (pain with a visual analogue score), and secondary outcomes will be (maximum mouth opening between edges of upper and lower incisors with millimeters, electrical activity with Electromyography, and quality of life assessed using the Oral Health Impact Profile questionnaire) The outcomes will be assessed pre-injection, 1month after injection, 3months after injection, and 6 months after injection

Timeline

Start
2024-10-01
Primary completion
2025-09-30
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 2 ml Other
Comparator Magnesium Sulfate Other / unclassified 2 ml Other